Precipio AML HemeScreen

Precipio launched a new HemeScreen panel for acute myeloid leukemia that returns results in four hours and determines the genetics of the disease. The test is intended to be used at oncology physician office laboratories and uses a single-sample plate to test blood samples for a variety of genes related to AML. It tests for FLT3, which can indicate how aggressive the disease is; CEBPA, which can provide prognostic information; NPM1, which can serve as a monitoring tool for minimal residual disease; IDH1, which is associated with decreased complete remission and IDH2 which is often associated with IDH1; and KIT, which reveals a poor prognosis and need for more aggressive treatment.